<DOC>
	<DOCNO>NCT01592292</DOCNO>
	<brief_summary>This prospective , multi-center , observational study evaluate efficacy safety MabThera ( rituximab ) participant rheumatoid arthritis respond intolerant first anti-TNF alpha therapy . Participants commence MabThera alternative anti-TNF alpha treatment second biological therapy . Data collect 12 month .</brief_summary>
	<brief_title>An Observational Study MabThera ( Rituximab ) Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance First Anti-TNF Alpha Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Adult participant , &gt; /=20 year age Participants rheumatoid arthritis , respond intolerant single antiTNF alpha therapy initiate MabThera alternative antiTNF alpha therapy Participants whose first antiTNF alpha treatment , second biological therapy give part clinical trial study rheumatoid arthritis Participants sign informed consent form</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>